债券简称：科思转债 债券代码：123192.SZ 股票简称：科思股份 股票代码：300856.SZ 南京科思化学股份有限公司 向不特定对象发行可转换公司债券 受托管理事务报告 （2024 年度） 债券受托管理人 中信证券股份有限公司 （广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座） 二〇二五年五月 重要声明 中信证券股份有限公司（以下简称"中信证券"）编制本报告的内容及信息 均来源于南京科思化学股份有限公司（以下简称"科思股份"、"公司"、"发 行人"）对外公告的《南京科思化学股份有限公司2024年年度报告》等相关公开 信息披露文件以及第三方中介机构出具的专业意见等。 本报告不构成对投资者进行或不进行某项行为的推荐意见，投资者应对相关 事宜做出独立判断，而不应将本报告中的任何内容据以作为中信证券所作的承诺 或声明。 1 | | | | 重要声明 1 | | | --- | --- | | 第一节 | 可转换公司债券概况 3 | | 第二节 | 债券受托管理人履行职责情况 14 | | 第三节 | 发行人 2024 年度经营情况和财务状况 16 | | 第四节 | 发行人募集资金使用及专项账户运作 ...

证券代码：300856 证券简称：科思股份 公告编号：2025-034 债券代码：123192 债券简称：科思转债 南京科思化学股份有限公司 关于完成董事会换届选举 及聘任高级管理人员、证券事务代表的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 南京科思化学股份有限公司（以下简称"公司"）于 2025 年 5 月 15 日召开 2024 年度股东大会，审议通过《关于公司董事会换届选举 暨提名第四届董事会非独立董事候选人的议案》《关于公司董事会换 届选举暨提名第四届董事会独立董事候选人的议案》;同日公司召开 第四届董事会第一次会议，审议通过《关于选举公司第四届董事会专 门委员会的议案》《关于选举公司第四届董事会董事长的议案》《关于 聘任公司高级管理人员的议案》《关于聘任公司证券事务代表的议案》。 公司第四届董事会的换届选举及高级管理人员、证券事务代表的聘任 已经完成，现将相关情况公告如下： 一、公司第四届董事会及专门委员会组成情况 1、董事长：周旭明先生 2、董事会成员： （1）非独立董事：周旭明先生、杨军先生、于鲁登先生、陶龙明 先生、曹晓如先生、何驰 ...

北京市竞天公诚律师事务所上海分所 关于 南京科思化学股份有限公司 2024 年度股东大会 之 法律意见书 上海市徐汇区淮海中路 1010 号嘉华中心 45 层 邮编：200031 Suite 45/F, K.Wah Centre, 1010 Huaihai Road (M), Xuhui District, Shanghai 200031, China 电话/Tel: +86 21 5404 9930 传真/Fax: +86 21 5404 9931 网址/Website: http://www.jingtian.com 二〇二五年五月 关于南京科思化学股份有限公司 2024 年度股东大会之法律意见书 致：南京科思化学股份有限公司 北京市竞天公诚律师事务所上海分所 法律意见书 北京市竞天公诚律师事务所上海分所 北京市竞天公诚律师事务所上海分所（下称"本所"）受南京科思化学股份 有限公司（下称"公司"）委托，就公司 2024 年度股东大会（下称"本次股东 大会"）召集、召开、表决程序、出席会议人员资格和有效表决等事项所涉及的 法律事项出具本法律意见书（下称"本法律意见书"）。 本所根据《中华人民共和国公司法》《 ...

证券代码：300856 证券简称：科思股份 公告编号：2025-032 债券代码：123192 债券简称：科思转债 南京科思化学股份有限公司 2024 年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形； 2、本次股东大会未涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 企业总部园 C1 栋 9 楼公司会议室。 4、会议召集人：公司董事会。 （一）会议召开情况 1、会议召开时间： （1）现场会议召开时间：2025 年 5 月 15 日（星期四）下午 14:30。 （2）网络投票时间：公司同时提供深圳证券交易所交易系统和 互联网投票系统供股东进行网络投票。 | 网络投票方式 | 投票时间 | | --- | --- | | 深圳证券交易所交易系统 | 2025 年 5 月 15 日上午 9:15-9:25，9:30- | | | 11:30；下午 13:00-15:00 | | 深圳证券交易所互联网投票系统 | 2025 年 5 月 15 日 9:15-15:00 | 2、会议的召开 ...

证券代码：300856 证券简称：科思股份 公告编号：2025-033 债券代码：123192 债券简称：科思转债 南京科思化学股份有限公司 第四届董事会第一次会议决议公告 本次董事会会议的召集、召开和表决程序符合有关法律、行政法 规、部门规章、规范性文件和《公司章程》的规定。 二、董事会会议审议情况 经与会董事认真审议，形成决议如下： （一）审议通过《关于选举公司第四届董事会专门委员会的议案》 根据《公司法》等法律法规和《公司章程》的规定，公司董事会 下设战略与可持续发展委员会、审计委员会、提名委员会和薪酬与考 核委员会，选举如下董事组成公司第四届董事会各专门委员会，任期 自本次董事会审议通过之日起至第四届董事会任期届满之日止： 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 南京科思化学股份有限公司（以下简称"公司"）第四届董事会 第一次会议于 2025 年 5 月 15 日以现场结合通讯方式召开，经全体董 事同意，本次会议豁免通知时间要求。会议应出席董事 9 名，实际出 席董事 9 名（其中 1 名董事以通讯方式出席）。经全体董事 ...

证券代码：300856 证券简称：科思股份 公告编号：2025-035 债券代码：123192 债券简称：科思转债 关于部分募投项目结项并将节余募集资金 永久补充流动资金及注销相关募集资金专户的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 南京科思化学股份有限公司（以下简称"公司"或"科思股份"） 首次公开发行股票募集资金投资项目"安徽圣诺贝化学科技有限公司 年产 500 吨防晒系列产品扩建项目"和"安庆科思化学有限公司科思 个人护理品研发项目"已实施完毕，公司拟对上述项目进行结项，并 将节余募集资金 163.54 万元（具体金额以实际结转时项目专户资金 余额为准）永久补充流动资金，用于与公司主营业务相关的生产经营 活动。上述结余募集资金补充流动资金后，公司首次公开发行股票募 集资金已全部使用完毕，公司将注销首次公开发行股票相关募集资金 专户。根据《深圳证券交易所上市公司自律监管指引第 2 号——创业 板上市公司规范运作》等有关规定，该事项无需提交公司董事会、股 东大会审议，亦无需监事会、保荐机构发表意见。现将具体情况公告 如下： 一、募集资金的基本情 ...

Core Viewpoint - The "3i Award - 2024 Scientific Instrument Industry User Attention Preferred Award" was held, recognizing 30 instruments that garnered significant user attention in the past year [1][2][5]. Group 1: Event Overview - The 18th China Scientific Instrument Development Annual Conference (ACCSI 2025) took place in Shanghai, attracting over 1,700 participants from various sectors including government, academia, and industry [2]. - The award ceremony for the "3i Award" was a highlight of the event, with notable figures presenting the awards to the winners [2][4]. Group 2: Award Significance - The "3i Award" has been awarded for 17 years, aimed at highlighting high-quality instruments that received significant user attention, serving as a reference for procurement decisions [5]. - Since its inception in 2007, the award has recognized over 400 instruments, receiving widespread acclaim from manufacturers and users alike [5]. Group 3: Award Winners - A detailed list of the award-winning instruments includes various categories such as TOC analyzers, rheometers, and gas chromatography-mass spectrometry (GC-MS) systems, showcasing a diverse range of technologies [5][6]. - Notable winners include the Elementar Total Organic Carbon Analyzer and the AVANCE NEO 600 Nuclear Magnetic Resonance Spectrometer, among others [5][6]. Group 4: About the 3i Award - The 3i Award, which stands for Innovative, Interactive, and Integrative, is organized by Instrument Information Network and aims to recognize outstanding contributions in the scientific instrument and testing industry [7]. - The award process is based on principles of fairness and transparency, relying on evaluations from industry experts and a large user base to select innovative products and commendable enterprises [7].

Core Viewpoint - The company is facing challenges in the sunscreen market due to slowing demand, increased competition, and adverse weather conditions affecting sales, leading to a decline in performance and pricing adjustments [2][5]. Group 1: Performance Decline and Response Strategies - Starting in the second half of 2024, the sunscreen market demand is expected to slow down, leading to a decrease in the shipment volume of sunscreen agents and a subsequent price reduction [2]. - The increase in inventory at the end of the reporting period is attributed to stockpiling of certain products, while new production lines are still ramping up capacity [2]. - In Q1 2025, the performance decline is expected to worsen due to increased rainy weather in Europe and North America, which negatively impacts the sales of sunscreen products and reduces downstream purchasing demand [2]. - The company is focusing on consolidating its leading position in sunscreen agents, advancing new product breakthroughs, and enhancing research investment in formulations [2]. - Additionally, the company aims to improve its management system, operational efficiency, and cost control while accelerating the construction of overseas bases [2]. Group 2: Market Expansion in Personal Care Ingredients - In Q3 2023, the company successfully launched 12,800 tons/year of amino acid surfactants and 3,000 tons/year of the new anti-dandruff agent pyrithione ethanolamine salt (PO), with initial results in customer certification and promotion [3]. - The company plans to strengthen market development by providing customized solutions to ensure project efficiency and effectiveness [3]. Group 3: Capacity Utilization and Market Competitiveness - The overall capacity utilization rate for cosmetic active ingredients and their raw materials in 2024 is affected by the ramp-up of new production lines [4]. - The company is a major global manufacturer of sunscreen agents, holding over 20% market share, with strong competitiveness in sunscreen and synthetic fragrance sectors [4]. - Core competitive advantages include a rich product structure, innovative R&D, optimized production and quality management, and collaboration with high-quality customers [4]. Group 4: Industry Outlook and Overseas Factory Progress - The global personal care products industry is stabilizing, with intensified competition in the sunscreen market, yet the overall market potential remains significant [5]. - Leading raw material manufacturers with comprehensive systems, international layouts, and stable supply capabilities are expected to further strengthen their advantages [5]. - The construction of the company's personal care products production base in Malaysia is progressing well, with product launches expected in the second half of this year [6]. Group 5: Product Pricing Strategy - The company states that the prices of its main products will follow market trends, and future adjustments will consider overall market conditions [7].

Group 1: Performance Overview - The company's performance decline is attributed to price reductions in sunscreen agents due to decreased market demand and increased competition [3][4] - In Q1 2025, the decline in performance is expected to continue, influenced by adverse weather conditions in Europe and North America, leading to lower sales during the peak season [4] - The gross profit margin of the main business has decreased, impacting net profit and earnings per share [4] Group 2: Market and Product Development - The company has a production capacity of 12,800 tons/year for amino acid surfactants and 3,000 tons/year for the new anti-dandruff agent, which have been successfully launched [5][6] - The sunscreen product market share exceeds 20% globally, with the company being a leading manufacturer in this sector [6] - The company is focusing on enhancing market development and providing customized solutions to downstream clients [5][6] Group 3: Strategic Responses - To counteract market fluctuations, the company is concentrating resources to maintain its leading position in sunscreen agents and is investing in research and development [4] - The management system and processes are being improved to enhance operational efficiency and cost control [4] - The company is also accelerating the construction of overseas bases to strengthen its risk management capabilities [4] Group 4: Future Outlook - The global personal care market is expected to grow steadily, with sunscreen and hair care products remaining high-demand categories [6] - The company is building a personal care production base in Malaysia, with products expected to be launched in the second half of the year [7] - Future price adjustments for products will depend on market supply and demand, costs, and the company's strategic development [8]

Group 1 - The global sunscreen market is entering an adjustment period in 2024, and the company, as an industry leader, is facing significant challenges with a year-on-year revenue decline of 5.16% and a net profit drop of 23.33% [1] - The structural decline in the sunscreen business is attributed to over-reliance on this core category, which contributes over 85% of revenue, facing a market demand inflection point in 2024 due to prolonged inventory digestion and competitive pricing pressures [2] - The company is experiencing a severe mismatch between production plans and market demand, with inventory levels increasing by 47.96% year-on-year, leading to deteriorating inventory turnover days [3] Group 2 - The strategic choices made by the company have exacerbated operational risks, including a significant increase in fixed assets and the construction of new capacity in Malaysia facing overcapacity risks before even being operational [3] - The company maintains a high dividend policy of 3 yuan per 10 shares, which is seen as a near-overdrawn approach given the halved net profit, further weakening the funds available for technological innovation [3] - To navigate its current predicament, the company needs to accelerate inventory liquidation and reduce non-core capacity investments in the short term, while redefining its competitive advantages in the long term through technological innovation and extending into high-value downstream products [4]